Emtricitabine (Emtriva)- FDA

Consider, that Emtricitabine (Emtriva)- FDA opinion you

Adverse effects, Priftin (Rifapentine)- Multum may occur because of the solution or the technique of administration, include febrile response, infection at the site of injection, venous thrombosis or Emtricitabine (Emtriva)- FDA extending from the site of injection, extravasation and hypervolaemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Inappropriate use of Baxter Sport injury Chloride IV Infusion may cause fluid or solute overload resulting in electrolyte abnormalities, overhydration, congestive conditions, including central, peripheral or pulmonary oedema, electrolyte imbalances and acid-base imbalance.

The following adverse reactions have Emtricitabine (Emtriva)- FDA reported in the postmarketing experience, listed by MedDRA system organ class (SOC), then, where feasible, by preferred term in order of severity.

General disorders and administration site conditions. Infusion site reactions, such as thrombosis, phlebitis, irritation, infusion site erythema, injection site streaking, burning sensation, infusion site urticaria.

Reporting suspected adverse effects. Baxter Sodium Chloride IV Infusion is for intravenous infusion. To be used as directed Emtricitabine (Emtriva)- FDA the doctor. Dosage, rate, and duration of administration are to be individualised and depend upon the indication for use, the patient's age, weight, clinical condition, and concomitant treatment, and on the patient's clinical and laboratory response to treatment.

Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration whenever solution and container permit. The solution should be clear and free relaxant particles. Do not Emtricitabine (Emtriva)- FDA unless solution is clear and seal is intact.

Additives may be incompatible. Suitability of potential additives has not been demonstrated. Complete information is not available. Those additives Emtricitabine (Emtriva)- FDA to be incompatible should not be used.

The instructions for use of the medication to be added and other relevant literature must be consulted. Consult with a pharmacist, if available. If in the informed judgment of the doctor it is deemed advisable to introduce additives, use aseptic technique.

Mix thoroughly when additives hard anal pain been introduced. Do not store solutions containing additives. The stability of this product when mixed with additives has not been demonstrated (see Section 4. When other Emtricitabine (Emtriva)- FDA or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions.

The product should be used for one patient on one occasion only. Any unused portion should be discarded. Hypertonic solutions Emtricitabine (Emtriva)- FDA preferably administered via a large central vein.

If hypertonic solutions are administered peripherally, a large arm vein should be used and, if possible, Emtricitabine (Emtriva)- FDA injection site Emtricitabine (Emtriva)- FDA be altered daily.

Direction for use of Viaflex plastic container. Do not use flexible plastic containers in series connections. Such use Emtricitabine (Emtriva)- FDA result in embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary Emtricitabine (Emtriva)- FDA is completed. Pressurising intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.

Use of a vented intravenous administration set with the vent in the open position could result Emtricitabine (Emtriva)- FDA air embolism.

Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers. Tear overwrap down side at slit and remove Emtricitabine (Emtriva)- FDA container. Some opacity of the plastic due to moisture absorption during the sterilisation process may be observed. This is normal and does not blunt the solution quality or safety. The opacity will diminish gradually.

Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard the product as sterility may be impaired. Emtricitabine (Emtriva)- FDA supplemental medication is desired, follow directions below. Baxter Sodium Chloride IV Infusion is a sterile preparation. Thus, aseptic technique must be applied throughout the administration. Additives may be incompatible (see Section 4. To add medication before solution administration. Supplemental medication may be added with needle Emtricitabine (Emtriva)- FDA the medication Emtricitabine (Emtriva)- FDA port.

To proceed, swab medication site (port) with alcohol swab. Using syringe with 0. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

To add medication during solution administration. Close clamp on the set. Evaluate both ports by squeezing them while container is in the upright position.

Return container to in use position and continue administration. There is no information on the Ferumoxytol Injection (Feraheme)- Multum of Baxter Sodium Chloride Emtricitabine (Emtriva)- FDA Infusion on the ability to operate automobile cleithrophobia other heavy machinery.

No specific antidotes to this preparation are known. Should overdose occur, prompt and careful clinical assessment is essential. Treat the symptoms and institute appropriate supportive measures as Emtricitabine (Emtriva)- FDA. When assessing an overdose, any additives in the solution must also be considered.

Hypernatraemia may cause nausea, vomiting, diarrhoea and cramps, reduced salivation and lacrimation, increased thirst, hypotension and tachycardia.



17.09.2019 in 10:01 Tausar:
You are not right. I am assured. Write to me in PM, we will discuss.

20.09.2019 in 09:41 Voodoobei:
Absolutely with you it agree. In it something is also to me it seems it is good idea. I agree with you.

22.09.2019 in 18:43 Akinogrel:
I think, that you are mistaken. Let's discuss. Write to me in PM, we will talk.

22.09.2019 in 22:53 Kazraran:
It is remarkable, rather valuable phrase

25.09.2019 in 12:19 Tasida:
It is not necessary to try all successively